.cls-1,.cls-3{fill:#083782;}.cls-2,.cls-3{fill-rule:evenodd;}.cls-2{fill:url(#linear-gradient);} Innovative Targeted and Immune-Mediated Cancer Therapies PIPELINE Developing first-in-class small molecule product candidates with broad potential benefit to patients LEARN MORE SCIENCE Modulating validated and new pathways to develop novel therapeutics LEARN MORE NEWS NOVEMBER 18, 2021 Tempest Announces First Patient Dosed with TPST-1495 in Combination with Pembrolizumab NOVEMBER 12, 2021 Tempest Presents Data Supporting the Dual Mechanism of TPST-1495 as an Optimal Approach for Targeting the Prostaglandin Pathway in Cancer NOVEMBER 10, 2021 Tempest Reports Third Quarter 2021 Financial Results and Provides Corporate Highlights MORE NEWS EVENTS MONDAY, NOVEMBER 22ND, 2021 AT 10:00 AM EASTERN Piper Sandler 33rd Annual Virtual Healthcare Conference Listen: Webcast THURSDAY, NOVEMBER 18TH, 2021 AT 8:00 AM EASTERN Jefferies London Healthcare Conference Listen: Webcast MONDAY, MARCH 29TH, 2021 AT 8:30 AM EASTERN Tempest and Millendo Proposed Merger Investor Call Listen: Webcast Download: Proposed Merger of Tempest and Millendo [PDF] © 2021 Tempest Therapeutics, Inc. All rights reserved. Website Design: Hane Chow, Inc.

Skip to main navigation Home News & Events Stock Information Corporate Governance Financials & Filings Investor Resources Investor FAQs Email Alerts Contact IR Investor FAQs When was Tempest founded? Tempest was founded in 2011 and incubated by Versant Ventures, and emerged as Tempest in 2017 Where is Tempest headquartered? When did Tempest go public? On what stock exchange and under what symbol are Tempest shares traded? Who do I contact with inquiries related to my stock, such as address changes, transferring stock, or replacing lost stock certificates? Does Tempest have a direct stock purchase plan? Does Tempest issue dividends on its common stock? What is the Tempest CUSIP number? Who is an external legal counsel for Tempest? Who is Tempest’s independent auditors? Where do I find Form 8937? When is the company’s fiscal year end? Who can I contact for more information? © 2021 Tempest Therapeutics. All rights reserved.

.cls-1,.cls-3{fill:#083782;}.cls-2,.cls-3{fill-rule:evenodd;}.cls-2{fill:url(#linear-gradient);} Developing therapeutics designed to effectively treat cancer. Tempest Therapeutics is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. The company’s leadership is comprised of experienced oncology drug discovery and development professionals who share a common goal of advancing novel therapeutics that will bring meaningful benefit to patients. Tempest is fortunate to have the support of a leading investor syndicate that shares our vision. VIEW OUR LEADERSHIP VIEW OUR BOARD OF DIRECTORS VIEW OUR ADVISORY BOARD © 2021 Tempest Therapeutics, Inc. All rights reserved. Website Design: Hane Chow, Inc.